Provoked Localized Vulvodynia Clinical Trial
Official title:
Remote Mindfulness-Education Intervention for Women With Provoked Localized Vulvodynia: A Randomized Clinical Study
Verified date | November 2023 |
Source | Oregon Health and Science University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a study designed to learn more about the use of an online remote education and mindfulness practice program for the pain and anxiety associated with provoked localized vulvodynia.
Status | Enrolling by invitation |
Enrollment | 46 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - Reported dyspareunia for at least 3 months in non-pregnant, healthy women over aged 18 years old and estrogen replete with confirmed diagnosis of provoked localized vulvodynia (PVL) or positive Q-tip test, meeting Friedrich's criteria for PLV. - Ability to insert a regular Tampax® tampon - Phone access - Cellular phone with ability to download applications - Reliable Internet Access Exclusion Criteria: - Pregnancy - Active sexual counseling or mindfulness training (within 6 months of study) - Any other clinical reason for dyspareunia (endometriosis pain, chronic pelvic pain, vulvar dermatoses such as psoriasis, lichen sclerosus, etc). - Unable or unwilling to complete baseline assessments or agree to be randomized. - Non-English speaking, as Headspace® is not validated in other languages - Actively engaged in a meditative practice |
Country | Name | City | State |
---|---|---|---|
United States | Oregon Health & Science University | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Oregon Health and Science University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Female Sexual Distress Scale (FSDS) at 8 weeks | The change in distress relating to sexual activity, measured by a change in the FSDS from baseline (study enrollment) survey. Participants will complete a Female Sexual Distress Scale (FSDS) survey to rate their feelings associated with sexual activities. Survey questions are on a number scale of 0 (Never) to 4 (Always). The FSDS surveys will be completed at baseline and 8 weeks after study enrollment. | Baseline & 8 weeks | |
Secondary | Change in Tampon Test Pain Scores at 8 weeks | The change in tampon test pain scores (a validated tool that measures introital pain). The tampon test is a validated tool used to measure (vulva) vestibular skin pain by having participants insert and remove a tampon. Participants will be asked to rate their pain along a 100 mm Visual Analog Scale on a scale of 0 (No pain) to 10 (pain as bad as you can imagine). This test will occur at baseline and 8 weeks after enrollment. | Baseline & 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02712814 -
Subtypes of Provoked Vestibulodynia
|
||
Completed |
NCT02919813 -
M-gCBT for Women With Provoked Localized Vulvodynia
|
N/A |